欧洲IVF监测联盟登记处20年:与其他两个地区登记处的比较
该研究比较了1997至2016年欧洲EIM/ESHRE、美国CDC及澳新ANZARD三大ART登记处的数据变化。结果显示三地ART治疗量均大幅增长,新技术采纳延迟,并发症记录零散;欧洲存在启动周期数低报。冷冻胚胎移植分娩率在美国和澳新已超新鲜周期,欧洲尚未。
要点
- 1997-2016年ART治疗量增长:欧洲5.3倍,美国4.6倍,澳新3.0倍。
- 冻融周期每移植分娩率在美国2012年、澳新2013年超过新鲜周期,欧洲尚未。
- 自2012年起三登记处最常见不良事件为早产(<37周)。
核心结论
- 三个地区登记处记录了连贯且相似的变化,但强度和速度不同;新技术采纳明显延迟,偶发并发症和不良事件仅零星记录。
研究设计与样本
- 回顾性分析比较EIM(2001-2020年发表报告)、CDC及ANZARD公布的1997-2016年ART数据,使用X2 log-rank分析评估数据集差异。
主要发现
- 1997-2016年记录ART治疗数增长:欧洲5.3倍,美国4.6倍,澳大利亚和新西兰3.0倍。
- 注册治疗模式数:欧洲从3种增至7种,美国从4种增至10种,澳大利亚和新西兰从5种增至8种。
- 冻融周期每胚胎移植分娩率在美国2012年、澳大利亚和新西兰2013年超过新鲜周期,欧洲尚未超过。
- 自2012年起,三个登记处记录的最常见ART不良事件为早产(<37周)。
- 母体死亡、卵巢过度刺激综合征、出血和感染仅由EIM和ANZARD记录。
关键数值与推荐
- 1997年23个欧洲国家中约78.1%的已知ART机构提交数据,2016年40个国家中该比例升至91.8%。
- 欧洲存在启动治疗周期数的相当程度低报。
- 所有地区双胚胎及以上移植周期数减少,多胎分娩减少。
临床怎么用
- 临床应关注ART治疗模式多样化及冷冻保存上升带来的安全性改善,同时需优化监管和数据质量保证。
- 解读欧洲ART数据时需谨慎,因各国法律背景和数据收集方法差异大,低报和不一致仍存在。
局限性
- 欧洲各国及三个登记处之间数据收集和报告方法差异很大。
- ART监管法律背景越好,数据集越完整;在全部欧洲国家建立法定报告义务及适当质量控制前,报告数字和发生率应谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: How has the performance of the European regional register of the European IVF-monitoring Consortium (EIM)/European Society of Human Reproduction and Embryology (ESHRE) evolved from 1997 to 2016, as compared to the register of the Centres for Disease Control and Prevention (CDC) of the USA and the Australia and New Zealand Assisted Reproduction Database (ANZARD)? SUMMARY ANSWER: It was found that coherent and analogous changes are recorded in the three regional registers over time, with a different intensity and pace, that new technologies are taken up with considerable delay and that incidental complications and adverse events are only recorded sporadically. WHAT IS KNOWN ALREADY: European data on ART have been collected since 1997 by EIM. Data collection on ART in Europe is particularly difficult due to its fragmented political and legal landscape. In 1997, approximately 78.1% of all known institutions offering ART services in 23 European countries submitted data and in 2016 this number rose to 91.8% in 40 countries. STUDY DESIGN, SIZE, DURATION: We compared the changes in European ART data as published in the EIM reports (2001-2020) with those of the USA, as published by CDC, and with those of Australia and New Zealand, as published by ANZARD. PARTICIPANTS/MATERIALS, SETTING, METHODS: We performed a retrospective analysis of the published EIM data sets spanning the 20 years observance period from 1997 to 2016, together with the published data sets of the USA as well as of Australia and New Zealand. By comparing the data sets in these three large registers, we analysed differences in the completeness of the recordings together with differences in the time intervals on the occurrence of important trends in each of them. Effects of suspected over- and under-reporting were also compared between the three registers. X2 log-rank analysis was used to assess differences in the data sets. MAIN RESULTS AND THE ROLE OF CHANCE: During the period 1997-2016, the numbers of recorded ART treatments increased considerably (5.3-fold in Europe, 4.6-fold in the USA, 3.0-fold in Australia and New Zealand), while the number of registered treatment modalities rose from 3 to 7 in Europe, from 4 to 10 in the USA and from 5 to 8 in Australia and New Zealand, as published by EIM, CDC and ANZARD, respectively. The uptake of new treatment modalities over time has been very different in the three registers. There is a considerable degree of underreporting of the number of initiated treatment cycles in Europe. The relationship between IVF and ICSI and between fresh and thawing cycles evolved similarly in the three geographical areas. The freeze-all strategy is increasingly being adopted by all areas, but in Europe with much delay. Fewer cycles with the transfer of two or more embryos were reported in all three geographical areas. The delivery rate per embryo transfer in thawing cycles bypassed that in fresh cycles in the USA in 2012, in Australia and New Zealand in 2013, but not yet in Europe. As a result of these changing approaches, fewer multiple deliveries have been reported. Since 2012, the most documented adverse event of ART in all three registers has been premature birth (<37 weeks). Some adverse events, such as maternal death, ovarian hyperstimulation syndrome, haemorrhage and infections, were only recorded by EIM and ANZARD. LIMITATIONS, REASONS FOR CAUTION: The methods of data collection and reporting were very different among European countries, but also among the three registers. The better the legal background on ART surveillance, the more complete are the data sets. Until the legal obligation to report is installed in all European countries together with an appropriate quality control of the submitted data the reported numbers and incidences should be interpreted with caution. WIDER IMPLICATIONS OF THE FINDINGS: The growing number of reported treatments in ART, the higher variability in treatment modalities and the rising contribution to the birth rates over the last 20 years point towards the increasing impact of ART. High levels of completeness in data reporting have been reached, but inconsistencies and inaccuracies still remain and need to be identified and quantified. The current trend towards a higher diversity in treatment modalities and the rising impact of cryostorage, resulting in improved safety during and after ART treatment, require changes in the organization of surveillance in ART. The present comparison must stimulate all stakeholders in ART to optimize surveillance and data quality assurance in ART. STUDY FUNDING/COMPETING INTEREST(S): This study has no external funding and all costs are covered by ESHRE. There are no competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- De Geyter C, Wyns C, Calhaz-Jorge C, et al. 20 years of the European IVF-monitoring Consortium registry: what have we learned? A comparison with registries from two other regions. Hum Reprod. 2020. PMID: 33188410. doi:10.1093/humrep/deaa250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。